Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.78 |
| ▸ | HPGD | P15428 | 3/20 | 0.78 |
| ▸ | LMNA | P02545 | 2/20 | 0.78 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.78 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.78 |
| ▸ | MAPT | P10636 | 5/20 | 0.74 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | MAOA | P21397 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.69 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.63 |
| ▸ | MYC | P01106 | 1/20 | 0.62 |
| ▸ | MAX | P61244 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8615717 | 0.97 | MAOB (0.78) | MAOBHPGDLMNAPLA2G1BATG4B | |
| SCHEMBL9123997 | 0.88 | MAOB (1.00) | MAOBHPGDLMNAPLA2G1BATG4B | |
| SCHEMBL5464396 | 0.87 | MEN1 (0.74) | MAOBHPGDLMNAPLA2G1BATG4B | |
| SCHEMBL9530086 | 0.84 | MAPT (0.76) | MAOBHPGDLMNAPLA2G1BATG4B | |
| SCHEMBL6816138 | 0.84 | MAPT (0.59) | MAOBHPGDLMNAPLA2G1BATG4B | |
| SCHEMBL4355796 | 0.84 | MAPT (0.66) | MAOBHPGDLMNAPLA2G1BATG4B | |
| SCHEMBL26485880 | 0.84 | LMNA (0.76) | MAOBHPGDLMNAPLA2G1BATG4B | |
| SCHEMBL26485863 | 0.83 | MAPT (0.64) | MAOBHPGDLMNAPLA2G1BATG4B | |
| SCHEMBL26485849 | 0.83 | MAPT (1.00) | HPGDLMNAMAPTMAPK1MEN1 | |
| SCHEMBL8612547 | 0.83 | MAOB (0.92) | MAOBHPGDLMNAMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230134821-A1 | MYC-MAX INHIBITOR COMPOUND THERAPEUTICS FOR CANCER TREATMENT, METHODS AND USES ASSOCIATED THEREWITH | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2023-05-04 | — | — | US | disclosed |
| US-20230134821-A1 | MYC-MAX INHIBITOR COMPOUND THERAPEUTICS FOR CANCER TREATMENT, METHODS AND USES ASSOCIATED THEREWITH | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2023-05-04 | — | — | US | disclosed |
| EP-0299533-B1 | HIGH POTENCY SWEETENING AGENTS | THE NUTRASWEET COMPANY (a Delaware corporation) (US) | 1993-04-07 | — | — | EP | disclosed |
| WO-1989000563-A1 | HIGH POTENCY SWEETENING AGENTS | THE NUTRASWEET COMPANY (US) | 1989-01-26 | — | — | WO | disclosed |
| EP-0299533-A2 | High potency sweetening agents | THE NUTRASWEET COMPANY (a Delaware corporation) (US) | 1989-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230134821-A1 | MYC-MAX INHIBITOR COMPOUND THERAPEUTICS FOR CANCER TREATMENT, METHODS AND USES ASSOCIATED THEREWITH | MYC, MYCBP, MAX | MAOB 2387/4885HPGD 3384/4885LMNA 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.